Dr. Reddy`s Laboratories Operating Income

The latest operating income for RDY is $30B as of September 2026. That compares with $71B in the prior-year period — down 58.5% year over year. Investors often review this figure alongside Dr. Reddy`s Laboratories's historical trend and sector peers before judging valuation or financial health.

Over the past year, RDY's operating income moved from $71B to $30B — a 58.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Dr. Reddy`s Laboratories's operating scale or balance-sheet position.

A operating income figure of $30B for RDY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting RDY's operating income ($30B), review year-over-year change from $71B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Dr. Reddy`s Laboratories's operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.